Physician

Alan Saven, M.D.

According to 2025 Medicare claims, Alan Saven, M.D. (NPI: 1184680399) practices hematology/oncology in the San Diego-Chula Vista-Carlsbad, CA market, with the plurality of this provider's patient population coming from San Diego, CA. This provider's primary affiliated billing organization is SCRIPPS HEALTH (NPI: 1275899072; TIN: 232380812) and primary practice location at 92037-1027. Saven is affiliated with the Scripps Accountable Care Organization, LLC (ACO ID: A3521), participating under the MSSP model.

Saven's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,263 traditional Medicare patients, billed 187,297 HCPCS/CPT codes, and received $2,949,417 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,379 prescription claims across 228 beneficiaries totaling $9,006,938 in drug costs, led by Lenalidomide (Lenalidomide). Open Payments data shows 43 records totaling $17,122. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,520,940 to $9,006,938. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	799	145,264	$2,269,610
2016	861	173,141	$2,478,452
2017	797	144,832	$2,436,308
2018	802	136,352	$2,903,859
2019	802	133,779	$2,588,017
2020	796	164,459	$2,873,627
2021	941	133,540	$2,279,074
2022	1,069	122,632	$2,331,885
2023	1,022	152,016	$2,597,549
2024	1,263	187,297	$2,949,417

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	136	816	$2,520,940
2016	178	1,090	$4,253,679
2017	205	1,277	$5,382,612
2018	217	1,468	$5,965,823
2019	240	1,196	$5,324,655
2020	205	1,524	$7,803,484
2021	218	1,389	$7,820,419
2022	223	1,387	$7,758,987
2023	232	1,442	$8,086,384
2024	228	1,379	$9,006,938

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	100	100	$172
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	152	355	$148
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	271	271	$126
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	793	1,564	$99
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	134	324	$54

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	149	4,172	$1,923,109
Imbruvica	Ibrutinib	61	1,856	$1,237,002
Jakafi	Ruxolitinib Phosphate	66	2,040	$1,179,184
Revlimid	Lenalidomide	63	1,757	$1,065,529
Brukinsa	Zanubrutinib	70	2,100	$1,039,460

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	43	$17,122	BeiGene USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alan Saven, M.D.?

Tedicare shows public-source Medicare data for Alan Saven, M.D. (NPI 1184680399), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alan Saven, M.D. have ACO affiliation data?

Alan Saven, M.D. is shown with ACO affiliation data for Scripps Accountable Care Organization, LLC (MSSP, ACO ID A3521).

What billing organization is linked to Alan Saven, M.D.?

Alan Saven, M.D. is linked to SCRIPPS HEALTH (billing NPI 1275899072) in the available physician profile data.

Does Alan Saven, M.D. have Open Payments data?

Alan Saven, M.D. has 43 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.